000118002 001__ 118002
000118002 005__ 20240319081026.0
000118002 0247_ $$2doi$$a10.3390/jpm12050658
000118002 0248_ $$2sideral$$a129133
000118002 037__ $$aART-2022-129133
000118002 041__ $$aeng
000118002 100__ $$aChaure-Pardos, Armando$$uUniversidad de Zaragoza
000118002 245__ $$aEffectiveness of Statins for Primary Prevention of Cardiovascular Disease in Low- and Medium-Risk Males: A Causal Inference Approach with Observational Data
000118002 260__ $$c2022
000118002 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118002 5203_ $$aIn this study, we analyzed the effectiveness of statin therapy for the primary prevention of cardiovascular disease (CVD) in low- and medium-risk patients. Using observational data, we estimated effectiveness by emulating a hypothetical randomized clinical trial comparing statin initiators with statin non-initiators. Two approaches were used to adjust for potential confounding factors: matching and inverse probability weighting in marginal structural models. The estimates of effectiveness were obtained by intention-to-treat and per-protocol analysis. The intention-to-treat analysis revealed an absolute risk reduction of 7.2 (95% confidence interval (CI95%), −6.6–21.0) events per 1000 subjects treated for 5 years in the matched design, and 2.2 (CI95%, −3.9–8.2) in the marginal structural model. The per-protocol analysis revealed an absolute risk reduction of 16.7 (CI95%, −3.0–36) events per 1000 subjects treated for 5 years in the matched design and 5.8 (CI95%, 0.3–11.4) in the marginal structural model. The indication for statin treatment for primary prevention in individuals with low and medium cardiovascular risk appears to be inefficient, but improves with better adherence and in subjectvs with higher risk.
000118002 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FIS/PI17-01704
000118002 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118002 590__ $$a3.4$$b2022
000118002 592__ $$a0.665$$b2022
000118002 591__ $$aMEDICINE, GENERAL & INTERNAL$$b67 / 169 = 0.396$$c2022$$dQ2$$eT2
000118002 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2
000118002 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b42 / 106 = 0.396$$c2022$$dQ2$$eT2
000118002 594__ $$a2.6$$b2022
000118002 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118002 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza
000118002 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, Mª José$$uUniversidad de Zaragoza
000118002 700__ $$0(orcid)0000-0001-7587-9716$$aLallana, Mª Jesús
000118002 700__ $$0(orcid)0000-0003-1647-3462$$aMaldonado, Lina$$uUniversidad de Zaragoza
000118002 700__ $$0(orcid)0000-0002-5064-3763$$aCastel-Feced, Sara$$uUniversidad de Zaragoza
000118002 700__ $$0(orcid)0000-0002-4859-9054$$aLibrero, Julián
000118002 700__ $$0(orcid)0000-0002-9887-2629$$aCasasnovas, José Antonio$$uUniversidad de Zaragoza
000118002 700__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000118002 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000118002 7102_ $$14014$$2623$$aUniversidad de Zaragoza$$bDpto. Economía Aplicada$$cÁrea Métodos Cuant.Econ.Empres
000118002 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000118002 773__ $$g12, 5 (2022), 658 [10 pp.]$$pJ. pers. med.$$tJournal of Personalized Medicine$$x2075-4426
000118002 8564_ $$s409055$$uhttps://zaguan.unizar.es/record/118002/files/texto_completo.pdf$$yVersión publicada
000118002 8564_ $$s2773841$$uhttps://zaguan.unizar.es/record/118002/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118002 909CO $$ooai:zaguan.unizar.es:118002$$particulos$$pdriver
000118002 951__ $$a2024-03-18-16:42:08
000118002 980__ $$aARTICLE